Hospital for Sick Children (Toronto)

Celebrated Musician, TV Star and Music Executive KARDINAL OFFISHALL Named the Recipient of the 2023 Canada's Walk of Fame Allan Slaight Music Impact Honour

Retrieved on: 
Thursday, October 26, 2023
Mentorship, History, Billboard, Metro Toronto Convention Centre, Reynolds cancer charities, Organic, Executive, The Tide Is High, Just Dance, Record, Philanthropy, Kardinal Offishall, Netflix, Hospital for Sick Children (Toronto), WE Charity, A&R, Hospital, Got Talent, Def Jam Recordings, Film industry, T-Pain

A multi-award-winning Canadian music icon, producer, A&R executive, and philanthropist, Kardinal is a relentless force in shaping Canada's hip-hop scene and a champion of emerging homegrown talent.

Key Points: 
  • A multi-award-winning Canadian music icon, producer, A&R executive, and philanthropist, Kardinal is a relentless force in shaping Canada's hip-hop scene and a champion of emerging homegrown talent.
  • WATCH Kardinal's reaction video to receiving the Allan Slaight Music Impact Honour.
  • Internationally respected as one of Canada's most energetic and innovative talents, Kardinal has long been a staple in the global music scene.
  • His talents now extend beyond the music industry, adding TV star to his repertoire as a judge on Canada's Got Talent.

CPA Canada welcomes new board chair and vice-chair

Retrieved on: 
Friday, September 29, 2023
Hospital for Sick Children (Toronto), Canadian Western Bank, Power Corporation of Canada, WXN, CPA Canada, Thomson Reuters, Woman, Wilson, Organization, Retirement, Jones, CPA, Greater Toronto Area, FCA, Growth, FCPA, Hospital, KPMG, Management

TORONTO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Chartered Professional Accountants of Canada (CPA Canada) today announced the appointment of a new chair and vice-chair for its board of directors.

Key Points: 
  • TORONTO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Chartered Professional Accountants of Canada (CPA Canada) today announced the appointment of a new chair and vice-chair for its board of directors.
  • Wilson earned her accounting designation in 1993 and joined the CPA Canada Board of Directors in September 2021.
  • “I am confident that Beth, along with the board of directors will continue to find innovative ways to create a sustainable long-term future for CPA Canada and the profession.”
    As chair, Wilson will draw on her extensive leadership experience.
  • “I am honoured to serve on CPA Canada’s board as vice-chair and to continue working with Beth, my board colleagues, CPA employees and our partners.” said Jones.

Brain Canada’s flagship program awards $2.8 million for brain research

Retrieved on: 
Thursday, September 21, 2023
Hospital for Sick Children, Hospital for Sick Children (Toronto), University, David Azrieli, Brain Research, Ambition Institute, Public, CIHR, Research, Directory, Azrieli Center, Disorder, LOI, Pain, Neuroscience, University of Toronto, Myenteric plexus, Canadian Institutes of Health Research, Brain, Government of Canada, Hospital, Health, Health Canada, Peer review, Injury, Medical device, Health insurance

MONTREAL, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Supported by the Canada Brain Research Fund and anchored by a lead gift from the Azrieli Foundation, the Future Leaders in Canadian Brain Research program aims to accelerate novel and transformative research that will fundamentally change our understanding of nervous system function and dysfunction and their impact on health. In its fourth year, this flagship program is providing funding to its largest-ever cohort of researchers, with 28 recipients—almost 30% more researchers than previous years. Over the course of four years, the Future Leaders in Canadian Brain Research program has granted awards to a total of 88 promising early-career researchers. The program is made possible through a substantial contribution from the Azrieli Foundation, with support this year from The Erika Legacy Foundation, The Arrell Family Foundation, the Segal Foundation, and the Canadian Institutes of Health Research (CIHR).

Key Points: 
  • Over the course of four years, the Future Leaders in Canadian Brain Research program has granted awards to a total of 88 promising early-career researchers.
  • With the support of Brain Canada and its donors and partners, these visionary researchers are making substantial contributions to brain research across the country and around the world.
  • “Brain Canada is the leading foundation dedicated to advancing neuroscience in this country,” says Naomi Azrieli, Brain Canada Chair.
  • To date, Health Canada has invested $200 million through the CBRF which has been matched by Brain Canada Foundation and its donors and partners.

Mirum’s LIVMARLI® Now Authorized in Canada for Cholestatic Pruritus in Patients with Alagille Syndrome

Retrieved on: 
Tuesday, July 25, 2023
Biotechnology, Pharmaceutical, Health, Hospital for Sick Children (Toronto), Bile, Tuba Mirum (Paus), Life, Liver disease, Cholestasis, Liver injury, Multimedia, Inflammation, Hospital for Sick Children, Alagille syndrome, EMA, Publication, Genetic disorder, Patient, Child, Itch, Liver, Hospital, FDA, Lancet, Health Canada, PFIC, Cholestatic pruritus, Disease, Pharmaceutical industry, Nursing, ALGS, Hepatology

Cholestasis in ALGS is associated with pruritus which is among the most common indications for liver transplant in ALGS.

Key Points: 
  • Cholestasis in ALGS is associated with pruritus which is among the most common indications for liver transplant in ALGS.
  • “Today’s approval in Canada furthers our commitment to ensuring patients globally have a meaningful and effective treatment option for the unrelenting burden of cholestatic pruritus impacting patients and their families living with ALGS,” said Chris Peetz, president and chief executive officer at Mirum.
  • Results from these studies showing robust and meaningful improvements for patients with cholestatic pruritus associated with ALGS were featured in several publications, including The Lancet and Hepatology .
  • Regulatory submissions outside of the U.S., Canada and Europe are being pursued by partners and distributors in key markets globally.

The Garry Hurvitz Centre for Community Mental Health at SickKids Selects VitalHub to implement its TREAT Client Information System to Enhance Client Care

Retrieved on: 
Monday, July 24, 2023
RFP, Hospital for Sick Children (Toronto), Partnership, VHI, Child, Case management, Community mental health service, TSX, Mental health, Family therapy, Software, Nursing

TORONTO, July 24, 2023 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX:VHI) (OTCQX:VHIBF) is excited to announce a partnership with The Garry Hurvitz Centre for Community Mental Health at SickKids (GH-CCMH), a leading child and youth mental health centre in Toronto, to implement their TREAT Client Information & Care Coordination software.

Key Points: 
  • TORONTO, July 24, 2023 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX:VHI) (OTCQX:VHIBF) is excited to announce a partnership with The Garry Hurvitz Centre for Community Mental Health at SickKids (GH-CCMH), a leading child and youth mental health centre in Toronto, to implement their TREAT Client Information & Care Coordination software.
  • Following a comprehensive RFP process, GH-CCMH has entered into a five-year agreement with VitalHub to license their TREAT software.
  • With a reputation for excellence in children and youth mental health support services, GH-CCMH aims to enhance their services further by leveraging the power of this integrated electronic health record system.
  • By leveraging TREAT's capabilities, we will optimize operations, streamline workflows, and ultimately improve the overall client experience,” said Neill Carson, Executive Director, The Garry Hurvitz Centre for Community Mental Health at SickKids.

Mirum Pharmaceuticals to Present New LIVMARLI Data at the 2023 EASL Congress

Retrieved on: 
Wednesday, June 7, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Abstract, EASL, Hospital for Sick Children (Toronto), Sleep, Publication, Medication, Patient, Itch, Bilirubin, Progressive familial intrahepatic cholestasis, Hospital, European Association for the Study of the Liver, Congress, Safety, Pharmaceutical industry, Vaccine

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will present data at the upcoming International Liver Congress of the European Association for the Study of the Liver taking place June 21-24, 2023 in Vienna, Austria.

Key Points: 
  • Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will present data at the upcoming International Liver Congress of the European Association for the Study of the Liver taking place June 21-24, 2023 in Vienna, Austria.
  • Data from Mirum’s studies of LIVMARLI® (maralixibat) oral solution include oral and poster presentations:
    Abstract OS-072: Maralixibat leads to significant reductions in bilirubin for patients with Progressive Familial Intrahepatic Cholestasis: Data from MARCH-PFIC
    Oral presentation during Abstract Session 2: Immune-mediated and cholestatic diseases
    Poster presentation during Poster Session: Immune-mediated and cholestatic diseases
    Author: Dr. Binita Kamath, The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada
    WED-252: Maralixibat leads to significant reductions in pruritus and improvements in sleep for children with Progressive Familial Intrahepatic Cholestasis: Data from MARCH-PFIC
    Poster presentation during Poster Session: Immune-mediated and cholestatic disease
    WED-282: Analysis of safety in maralixibat-treated participants with Progressive Familial Intrahepatic Cholestasis: Data from MARCH-PFIC
    The abstracts are available on the EASL website and during the congress, the presentations will be available within the Publications and Presentations section on Mirum’s website.

New Research Puts a Multi-Billion Price Tag on Failure to Improve Children’s Health in Canada

Retrieved on: 
Wednesday, May 31, 2023
Seizure, Ottawa, Hospital for Sick Children (Toronto), Obesity, University, Public policy, Bullying, Public Health Agency of Canada, CHEO, Research, Mother, Economics, Social work, Social justice, Social return on investment, Investment, Child, Medicare, Father, First Nations, Hospital, Food, IWK, Public Health Agency, Education, Under Secretary of Agriculture for Research, Education, and Economics, Birth control, Nursing, Pharmaceutical industry, Health insurance, Health

“Pandemic restrictions have lifted and the recent acute pediatric crisis has waned, but the impacts will be felt for years to come.

Key Points: 
  • “Pandemic restrictions have lifted and the recent acute pediatric crisis has waned, but the impacts will be felt for years to come.
  • The research involves a multi-disciplinary team from the University of Calgary and the University of Toronto, including the faculties of Social Work, Public Policy, Health, Education and Economics.
  • Vivic Research, an economic consulting firm dedicated to advocating for social justice with data-driven research, partnered on the economic analysis of the social return on investment in children’s health.
  • Children First Canada graciously recognizes the support of the Public Health Agency of Canada, MITACS, The Hospital for Sick Children (SickKids), CHEO, and the IWK for making this report possible.

Radiant Biotherapeutics Emerges from Stealth Mode with $8 Million Seed Round and Two Pharma Partnerships

Retrieved on: 
Tuesday, April 25, 2023
FACIT, Hospital for Sick Children (Toronto), University, Therapy, Investment, Cancer, Pharmacokinetics, Research, Infection, Antibody, The Hospital, Principal, POC, Pharmaceutical industry, Vaccine, Radiant

TORONTO, April 25, 2023 (GLOBE NEWSWIRE) -- Radiant Biotherapeutics, a revolutionary antibody platform company developing multi-valent, multi-specific therapeutics emerged from stealth mode unveiling an $8 million seed financing and two significant pharmaceutical partnerships. The Company, based on foundational IP from the labs of Dr. Jean-Philippe Julien at The Hospital for Sick Children (SickKids) and Dr. Bebhinn Treanor at the University of Toronto, was created by Amplitude Ventures which also led the seed round along with launch partner, SickKids and additional investors Alexandria Investments, FACIT and Toronto Innovation Acceleration Partners (TIAP).

Key Points: 
  • TORONTO, April 25, 2023 (GLOBE NEWSWIRE) -- Radiant Biotherapeutics, a revolutionary antibody platform company developing multi-valent, multi-specific therapeutics emerged from stealth mode unveiling an $8 million seed financing and two significant pharmaceutical partnerships.
  • “This financing enables us to advance and validate our Multabody platform among several oncology programs with potential best-in-class profiles,” said Arthur J. Fratamico, President and Chief Executive Officer of Radiant.
  • “Radiant’s first-of-its-kind Multabody platform has the potential to transform antibody therapeutics,” said Bharat Srinivasa, founding CEO and Principal at Amplitude Ventures.
  • This proprietary platform has exciting potential to also create unique therapies targeting biological pathways not amenable to current antibody approaches.”

Homecare Hub Appoints Renowned Hospital Executive Dr. Michael Apkon to Board of Directors to Help Solve Society's Post-Acute Care Crisis

Retrieved on: 
Thursday, April 20, 2023
School, Yale University, Hospital for Sick Children (Toronto), Housing, University, CHOP, Tufts University, Ageing, Yale school, MBA, Doctor of Philosophy, Yale School of Management, Biomedical engineering, Government, Organization, Yale New Haven Health System, Acquisition, Tufts Medical Center, MD, The Hospital, Washington University School of Medicine, Management, Hospital, Children's Hospital of Philadelphia, Northwestern University, Medicine

Since 2021, Dr. Apkon has served as an advisor to Homecare Hub and he has become well acquainted with the team, the vision, and services offered.

Key Points: 
  • Since 2021, Dr. Apkon has served as an advisor to Homecare Hub and he has become well acquainted with the team, the vision, and services offered.
  • "I'm excited to continue working with the Homecare Hub Team as a member of the Board" said Dr. Apkon.
  • Homecare Hub has a unique solution that addresses the challenges that so many people face during difficult parts of life".
  • We believe that Dr. Apkon will continue to shape the future of healthcare in his role at Homecare Hub, as we aim to solve our looming post-acute care and aging crisis through our innovative solutions."

Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer

Retrieved on: 
Thursday, March 16, 2023
DSM-IV codes, LGG, Hospital for Sick Children (Toronto), Diarrhea, Progression-free survival, McKesson Corporation, Clinical trial, Hope, BRAF, Mutation, Research, Brain, Abdominal pain, PFS, BRAF V600, Lung, Rash, ASCO, Vomiting, Bleeding, Dizziness, American Society of Clinical Oncology, Novartis, MD, Patient, Melanoma, The Hospital, Annual general meeting, Nausea, St Saviour's and St Olave's Church of England School, FRCPC, Upper respiratory tract infection, Phase, FDA, Fever, Headache, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Thyroid cancer, ORR, Food, Fatigue, Medical imaging, Pharmaceutical industry, Dabrafenib

The FDA also approved liquid formulations of Tafinlar and Mekinist, marking the first time a BRAF/MEK inhibitor has been developed in a formulation suitable for patients as young as one year of age.

Key Points: 
  • The FDA also approved liquid formulations of Tafinlar and Mekinist, marking the first time a BRAF/MEK inhibitor has been developed in a formulation suitable for patients as young as one year of age.
  • These approvals make Tafinlar + Mekinist the first and only approved combination targeted therapy to treat pediatric patients with BRAF V600E LGG.
  • BRAF V600 mutations are present in 15-20% of pediatric LGGs and are associated with poor survival outcomes and less favorable response to chemotherapy4.
  • BRAF mutations have been identified as drivers of cancer growth across a wide range of solid tumors, and often have limited treatment options4,5.